LKFT
Lakefront Biotherapeutics N.V.Healthcare · $1.8B market cap
Verdict
We can't put a fair value on LKFT right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Earnings per share growth23.2% a year✓
Equity per share growth—?
Sales growth10.9% a year✓
Free cash flow growth—?
Return on invested capital5.1%✗
Follow LKFT
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds LKFT. Who we track
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works